Kato, Taigo http://orcid.org/0000-0002-8681-1407
Matsubara, Nobuaki
Shiota, Masaki
Eto, Masatoshi
Osawa, Takahiro
Abe, Takashige
Shinohara, Nobuo
Yasumizu, Yota
Tanaka, Nobuyuki
Oya, Mototsugu
Nishimoto, Koshiro
Hayashi, Takuji
Nakayama, Masashi
Kojima, Takahiro
Namikawa, Kenjiro
Fujisawa, Takao
Okano, Susumu
Hida, Eisuke
Nakamura, Yoshiaki
Bando, Hideaki
Yoshino, Takayuki
Nonomura, Norio
Funding for this research was provided by:
Japan Agency for Medical Research and Development (21ck0106656h0001)
Article History
Received: 24 July 2022
Accepted: 3 December 2022
First Online: 9 December 2022
Declarations
:
: The IMAGENE trial is conducted in accordance with the Declaration of Helsinki, the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, and the Clinical Trial Acts in Japan. Each trial has been approved by the institutional review board of Osaka University Hospital Certified Review Board.All patients were required to sign written informed consent.Registry and the Registration No. of the study/trial: This trial has been registered in the Japan Registry of Clinical Trials (jRCT2051210120).
: Not applicable.
: TK reports research funding supports from Takeda and Pfizer. NM reports honoraria from Janssen, Merck biopharma, and Sanofi and research funding supports from Janssen, AstraZeneca, Bayer, Roche, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, PRA Health Science, Takeda, Pfizer, Seagen, Chugai, Abbvie, and Novartis. MS reports honoraria from Janssen, AstraZeneca, and Astellas and research funding support from Daiichi Sankyo. ME reports honoraria from ONO, Takeda, Novartis, Pfizer, Bristol, Janssen, MSD, Merck, AstraZeneca, and Eisai and research funding support from Sanofi, Bayer, Astellas, ONO, and Takeda. TO reports honoraria from Takeda. MO reports honoraria from Bayer, Bristol, Novartis, Ono, Merck, Takeda, MSD, and Pfizer. KN reports honoraria from Ono, Novartis, MSD, and Bristol, and consulting fees from Novartis and MSD. YN reports honoraria from Chugai, Merck Biopharma, and Guardant Health AMEA, and research funding support from Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Seagen, and Roche Diagnostics. HB reports honoraria from Taiho, Ono, and Eli Lilly Japan, and research funding supportĀ from Ono. TY reports honoraria from Chugai, Merck, Bayer, Ono, and MSD, and research funding from MSD, Daiichi Sankyo, Ono, Taiho, Amgen, Sanofi, Pfizer, Genomedia, Sysmex, Chugai, and Nippon Boehringer Ingelheim. NN reports honoraria from Takeda, Janssen, AstraZeneca, Merck Biopharma, Ono, and Bristol.